8-K: STRATA Seeks Early XTRAC Reimbursement, Tripling Market

STRATA Skin Sciences is working with CMS to accelerate reimbursement for its XTRAC laser, expanding its addressable market to over 30 million patients, while also advancing litigation against LaserOptek.

Summary

• Working with the Centers for Medicare & Medicaid Services (CMS) to obtain temporary codes to accelerate access to expanded reimbursement for its XTRAC excimer laser treatment.
• The American Medical Association's CPT Editorial Panel approved updates to codes 96920-96922, expanding XTRAC reimbursement eligibility to include all inflammatory and autoimmune skin conditions (such as vitiligo, atopic dermatitis, and alopecia areata) in addition to psoriasis, effective January 1, 2027.
• Aims to make these expanded indications reimbursable as early as the 2026 rule cycle by securing temporary CMS codes.
• This acceleration is expected to effectively triple the addressable patient population to more than 30 million patients.
• Recent peer-reviewed publications support excimer laser therapy in combination with JAK inhibitors for treating vitiligo.
• The company's intellectual property portfolio includes patents for the use of JAK inhibitors in combination with excimer laser therapy.
• The Federal District Court agreed with the company's position to add LaserOptek Co. Ltd (LaserOptek Korea), the South Korean parent of LaserOptek America, as a defendant in the unfair competition lawsuit.
• The court also allowed the company to add C. Dalton, LLC, the entity that represented LaserOptek Korea's interests in the U.S., as another defendant in the lawsuit.

Sentiment

Score: 8

Explanation: The filing indicates significant positive developments for STRATA Skin Sciences, including a potential tripling of its addressable market for XTRAC treatments, accelerated reimbursement timelines, and favorable progress in its unfair competition lawsuit, all of which could substantially improve future revenue and market position.

Positives

• Potential to triple the addressable patient population for XTRAC to over 30 million patients due to expanded reimbursement eligibility.
• Accelerated reimbursement timeline for expanded XTRAC indications from January 1, 2027, to potentially the 2026 rule cycle.
• Improved treatment economics for both providers and the company due to expanded reimbursement.
• Strong support from members of the legislature, patient advocacy groups, and leading academic key opinion leaders for XTRAC expansion.
• New peer-reviewed studies validate the efficacy and safety of combining excimer laser therapy with JAK inhibitors for vitiligo, strengthening XTRAC's standing as a leading drug-free option.
• Successful addition of LaserOptek Co. Ltd (Korean parent) and C. Dalton, LLC as defendants in the unfair competition lawsuit, indicating progress in litigation.
• Potential for significant damages to be awarded to STRATA from the lawsuit.
• Holds intellectual property covering methods for localized treatment using JAK inhibitors and dosimeter-guided Excimer Laser.

Negatives

• The full CPT code expansion for XTRAC is not effective until January 1, 2027, requiring temporary codes for earlier access, which are not yet secured.
• Ongoing litigation against LaserOptek America and its affiliates, which can be resource-intensive and subject to legal uncertainties.

Risks

• Uncertainty in obtaining temporary CMS codes for accelerated reimbursement, which could delay market expansion.
• Actual results may differ materially from expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions, labor supply shortages, or supply chain interruptions.
• Risks associated with the company's ability to launch and sell products, develop social media and direct-to-consumer marketing campaigns, and build a leading franchise in dermatology and aesthetics.
• The ongoing lawsuit against LaserOptek America and its affiliates carries inherent litigation risks, including the potential for the Pallas physician offices and staff to face action by CMS for submitting reimbursement claims for non-reimbursable procedures.

Future Outlook

STRATA Skin Sciences aims to accelerate reimbursement for its XTRAC excimer laser treatment for expanded indications, potentially tripling its addressable patient population to over 30 million patients as early as the 2026 rule cycle, ahead of the official January 1, 2027 CPT code expansion. The company also anticipates potential significant damages from its ongoing unfair competition lawsuit.

Management Comments

• "Expanding access to XTRAC is about more than increasing device utilization and revenue per device its about helping millions of patients who are living with chronic, inflammatory skin conditions, with limited long term safe, efficacious and accessible treatment modalities." Dr. Dolev Rafaeli, President and CEO.
• "By working with CMS to secure temporary reimbursement ahead of 2027, we aim to bring this safe, effective, non-drug therapy to a broader patient population—more than 30 million people—sooner, while creating more substantial economic incentives for providers to deliver this care, for which they are paid vs. prescribing expensive, less effective medication for which they are not." Dr. Dolev Rafaeli, President and CEO.
• "Our confidence in this mission is reinforced by the huge support we have secured from members of the legislature, patient advocacy groups, and leading academic key opinion leaders." Dr. Dolev Rafaeli, President and CEO.
• "We are further encouraged by the growing body of peer-reviewed published clinical studies supporting Excimer Laser therapy, and pointing to new and enhanced applications, adding to the hundreds of other studies published over the years." Dr. Dolev Rafaeli, President and CEO.
• "These findings further strengthen XTRACs standing as a leading drug-free option and highlight its role to enhance patient outcomes in the era of next-generation therapies." Dr. Dolev Rafaeli, President and CEO.
• "STRATA is pleased to report that the Federal District Court has agreed with Stratas position that LaserOptek Co. Ltd, (LaserOptek Korea) the South Korean parent of LaserOptek America, should be added as a defendant in the lawsuit." Dr. Dolev Rafaeli, President and CEO.
• "It is encouraging that the court recognized what we believe to be the duplicitous actions of the defendants in attempting to hide and shield the Korean entity from the lawsuit." Dr. Dolev Rafaeli, President and CEO.
• "We are further gratified by the significant potential damages that may be awarded to STRATA." Dr. Dolev Rafaeli, President and CEO.
• "The addition of LaserOptek Korea and C. Dalton, LLC, the entity that represented LaserOptek Koreas interests in the U.S., clearly demonstrates that those parties should be held accountable for the knowingly false misrepresentations made as outlined in our unfair trade practices claim under the Lanham Act." Dr. Dolev Rafaeli, President and CEO.

Industry Context

The medical technology industry, particularly in dermatology, is seeing advancements in laser therapies and combination treatments for chronic skin conditions. The expansion of CPT codes for excimer lasers reflects a growing recognition of their efficacy, while the integration with emerging drug classes like JAK inhibitors signifies a trend towards multi-modal approaches to patient care. Litigation around unfair competition highlights the competitive landscape and importance of intellectual property in this sector.

Comparison to Industry Standards

• The expansion of CPT codes for XTRAC excimer laser treatments to include all inflammatory and autoimmune skin conditions, effective January 1, 2027, positions STRATA's technology to address a broader market, aligning with the industry trend of expanding indications for established medical devices.
• The reported success of combining 308-nm excimer-laser therapy with JAK inhibitors for vitiligo, as supported by peer-reviewed publications, demonstrates STRATA's alignment with cutting-edge, evidence-based treatment protocols in dermatology, potentially setting a new standard for combination therapies.
• STRATA's pursuit of temporary CMS codes to accelerate reimbursement to the 2026 rule cycle, ahead of the 2027 CPT code effective date, indicates an aggressive strategy to capitalize on market opportunities faster than typical industry adoption cycles for new reimbursement policies.

Legal Proceedings

• Ongoing lawsuit for unfair competition under the Lanham Act against LaserOptek America, LaserOptek Co. Ltd (South Korean parent), and C. Dalton, LLC.
• The original lawsuit was filed in August 2024 in the U.S. District Court of the Eastern District of Pennsylvania.
• Allegations include false advertising and unfair competition regarding the marketing and sale of Pallas lasers and reimbursement of psoriasis treatment procedures performed with Pallas lasers.
• The Federal District Court agreed to add LaserOptek Co. Ltd and C. Dalton, LLC as defendants.
• The company is encouraged by the significant potential damages that may be awarded to STRATA.
• The lawsuit highlights potential exposure for Pallas physician offices and staff to action by CMS for submitting reimbursement claims for non-reimbursable procedures.

Stakeholder Impact

• Shareholders: Potential for increased revenue, market share, and improved financial performance due to expanded XTRAC reimbursement and successful litigation outcomes, likely leading to positive share price impact.
• Patients: Millions of patients suffering from chronic inflammatory skin conditions (vitiligo, atopic dermatitis, alopecia areata) could gain earlier access to a safe, effective, non-drug treatment (XTRAC).
• Providers (Physicians): Improved treatment economics and increased incentives to deliver XTRAC care, as they are reimbursed for procedures rather than just prescribing medication.
• Competitors: Increased competition, particularly for companies like LaserOptek America facing litigation for alleged unfair practices, potentially impacting their market position and legal liabilities.

Next Steps

• Continue working with CMS to obtain temporary codes for accelerated XTRAC reimbursement.
• Continue prosecuting the lawsuit for unfair competition against LaserOptek America, LaserOptek Co. Ltd, and C. Dalton, LLC.
• Monitor the effective date of expanded CPT codes 96920-96922 on January 1, 2027.

Key Dates

Recommendation

The filing presents highly favorable developments for STRATA Skin Sciences, including a potential tripling of its addressable market for XTRAC treatments to over 30 million patients, accelerated reimbursement timelines for these expanded indications, and significant progress in its unfair competition lawsuit with potential for substantial damages. These factors collectively point to a strong growth trajectory and improved financial outlook, making it a compelling investment opportunity.

Keywords

STRATA Skin Sciences, SSKN, XTRAC, Excimer Laser, Medicare, CMS, CPT Codes, Reimbursement, Vitiligo, Psoriasis, Atopic Dermatitis, Alopecia Areata, Dermatology, Medical Technology, JAK Inhibitors, Litigation, Lanham Act, LaserOptek